These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29026141)

  • 21. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
    Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates.
    Martinon F; Kaldma K; Sikut R; Culina S; Romain G; Tuomela M; Adojaan M; Männik A; Toots U; Kivisild T; Morin J; Brochard P; Delache B; Tripiciano A; Ensoli F; Stanescu I; Le Grand R; Ustav M
    Hum Gene Ther; 2009 Nov; 20(11):1291-307. PubMed ID: 19627235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice.
    King DF; McKay PF; Mann JF; Jones CB; Shattock RJ
    PLoS One; 2015; 10(11):e0141557. PubMed ID: 26544970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans.
    Vogt A; Mahé B; Costagliola D; Bonduelle O; Hadam S; Schaefer G; Schaefer H; Katlama C; Sterry W; Autran B; Blume-Peytavi U; Combadiere B
    J Immunol; 2008 Feb; 180(3):1482-9. PubMed ID: 18209043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.
    Williams M; Ewing D; Blevins M; Sun P; Sundaram AK; Raviprakash KS; Porter KR; Sanders JW
    Vaccine; 2019 Jul; 37(32):4444-4453. PubMed ID: 31279565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
    Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
    PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
    Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
    Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
    Graham BS; Enama ME; Nason MC; Gordon IJ; Peel SA; Ledgerwood JE; Plummer SA; Mascola JR; Bailer RT; Roederer M; Koup RA; Nabel GJ;
    PLoS One; 2013; 8(4):e59340. PubMed ID: 23577062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
    Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
    PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
    Best SR; Peng S; Juang CM; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
    Vaccine; 2009 Sep; 27(40):5450-9. PubMed ID: 19622402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.